H.C. Wainwright upgraded Agenus (AGEN) to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus’ commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus selling U.S. manufacturing facilities to Zydus
- Agenus, Zydus enter $141M collaboration for BOT/BAL production orders
- Agenus presents new translational data at 2025 ASCO meeting
- Biotech Alert: Searches spiking for these stocks today
- Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI